Rizatriptan
Triptan for Acute Migraine Relief
Quick Facts About Rizatriptan
Key Takeaways About Rizatriptan
- Fast-acting migraine relief: Rizatriptan provides significant pain relief within 30 minutes in many patients, making it one of the fastest-acting oral triptans available
- Two convenient formulations: Available as conventional tablets and orodispersible wafers that dissolve on the tongue without water – ideal for patients with migraine-related nausea
- MAOIs are strictly contraindicated: Rizatriptan must not be used within 14 days of monoamine oxidase inhibitor (MAOI) therapy due to risk of dangerously high serotonin levels
- Dose reduction with propranolol: If you take propranolol (a beta-blocker used for migraine prevention), your rizatriptan dose must be reduced to 5 mg, with a maximum of 15 mg per 24 hours
- Limit use to prevent overuse headache: Do not use rizatriptan on more than 10 days per month to avoid medication-overuse headache (MOH)
What Is Rizatriptan and What Is It Used For?
Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist (triptan) used for the acute treatment of migraine headache with or without aura in adults. It relieves migraine pain, nausea, and sensitivity to light and sound, but does not prevent future migraine attacks.
Rizatriptan belongs to the triptan class of antimigraine medications. Triptans were developed specifically for migraine and represent a major advance over older, less selective treatments. Rizatriptan was first approved for medical use in 1998 and has been extensively studied in large randomised controlled trials involving thousands of patients.
Rizatriptan is indicated for the acute treatment of migraine attacks in adults, with or without aura. Migraine is a complex neurological condition characterised by recurrent episodes of moderate to severe headache, typically unilateral and pulsating, often accompanied by nausea, vomiting, photophobia (sensitivity to light), and phonophobia (sensitivity to sound). The International Headache Society (IHS) classifies migraine under primary headache disorders in the ICHD-3 classification.
It is important to understand that rizatriptan is an acute (abortive) treatment – it treats the migraine attack that is currently happening. It does not prevent future attacks and should not be taken prophylactically. For patients who experience frequent migraines (4 or more attacks per month), doctors may recommend separate preventive (prophylactic) medications such as propranolol, topiramate, amitriptyline, or CGRP monoclonal antibodies.
Rizatriptan is not indicated for the treatment of hemiplegic migraine, basilar migraine, tension-type headache, or cluster headache. It should only be used after a clear diagnosis of migraine has been established by a physician.
Rizatriptan is available in two formulations: conventional tablets that are swallowed with water, and orodispersible tablets (also known as wafers, lyophilisates, or melt tablets) that dissolve rapidly on the tongue without the need for water. The orodispersible form is particularly convenient for patients who experience nausea or vomiting during a migraine attack, making it difficult to swallow a conventional tablet.
What Should You Know Before Taking Rizatriptan?
Before starting rizatriptan, inform your doctor about any history of heart disease, stroke, uncontrolled high blood pressure, or liver problems. Rizatriptan is contraindicated with MAO inhibitors and should not be used within 24 hours of ergotamine or another triptan.
Contraindications
You should not take rizatriptan if any of the following apply to you:
- Allergy to rizatriptan or any of the other ingredients in this medicine
- Uncontrolled hypertension (high blood pressure that is not adequately managed with medication)
- Coronary artery disease (including angina pectoris, history of heart attack, or documented silent ischaemia)
- History of stroke or transient ischaemic attack (TIA)
- Peripheral vascular disease (narrowing of blood vessels in the legs or arms)
- Severe hepatic impairment (severe liver disease)
- Current use of MAO inhibitors or use within the past 14 days (e.g. phenelzine, tranylcypromine, moclobemide, linezolid)
- Use of ergotamine or ergotamine-type medications (e.g. dihydroergotamine, methysergide) within the past 24 hours
- Use of another triptan (e.g. sumatriptan, zolmitriptan, eletriptan) within the past 24 hours
Warnings and Precautions
Talk to your doctor or pharmacist before taking rizatriptan if you have or have had any of the following:
- Risk factors for coronary artery disease – including diabetes, high cholesterol, smoking, obesity, family history of heart disease, or being male over 40 or a postmenopausal woman. Your doctor may want to evaluate your cardiovascular status before prescribing rizatriptan
- Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders
- Liver disease – rizatriptan exposure may be increased, and a lower dose (5 mg) may be appropriate
- Phenylketonuria (PKU) – the orodispersible tablets contain aspartame, a source of phenylalanine
- Seizure disorder (epilepsy) – triptans may lower the seizure threshold in susceptible individuals
Pregnancy and Breastfeeding
The safety of rizatriptan during pregnancy has not been fully established. Animal studies at high doses have shown some adverse developmental effects. Human data are limited, although pregnancy registries have not identified a clear pattern of birth defects. Rizatriptan should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the foetus. Consult your doctor before taking rizatriptan if you are pregnant or planning to become pregnant.
Rizatriptan is excreted in animal milk, and it is not known whether it passes into human breast milk. If you are breastfeeding, consult your doctor before taking rizatriptan. As a precaution, you may be advised to avoid breastfeeding for 24 hours after taking a dose.
Driving and Operating Machinery
Migraine itself and treatment with rizatriptan can cause drowsiness and dizziness. You should not drive or operate machinery during a migraine attack or until you know how rizatriptan affects you. Wait until your symptoms have fully resolved before driving.
How Does Rizatriptan Interact with Other Drugs?
Rizatriptan has critical interactions with MAO inhibitors (strictly contraindicated), propranolol (requires dose reduction to 5 mg), ergotamine-containing medicines, and other triptans. Use with SSRIs or SNRIs carries a risk of serotonin syndrome.
Rizatriptan is primarily metabolised by monoamine oxidase-A (MAO-A). This metabolic pathway is central to understanding its most important drug interactions. Additionally, rizatriptan can interact with other serotonergic drugs, increasing the risk of the potentially life-threatening serotonin syndrome.
Contraindicated & Major Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| MAO Inhibitors (phenelzine, tranylcypromine, moclobemide, linezolid) | Antidepressant / Antibiotic | MAOIs block rizatriptan metabolism, causing plasma levels to increase by up to 119%. Severe risk of serotonin syndrome and hypertensive crisis | CONTRAINDICATED. Do not use rizatriptan within 14 days of MAOI use |
| Propranolol | Beta-blocker | Propranolol increases rizatriptan plasma levels by approximately 70% by inhibiting MAO-A-mediated first-pass metabolism | Reduce rizatriptan dose to 5 mg per dose; maximum 15 mg per 24 hours |
| Ergotamine / Dihydroergotamine | Ergot alkaloid | Additive vasospasm; risk of prolonged coronary artery constriction and myocardial ischaemia | Do not use within 24 hours of each other |
| Other Triptans (sumatriptan, zolmitriptan, eletriptan, etc.) | 5-HT1B/1D agonists | Additive serotonergic and vasoconstrictive effects | Do not use within 24 hours of another triptan |
Moderate Interactions – Serotonin Syndrome Risk
Using rizatriptan together with other serotonergic medications can cause serotonin syndrome, a potentially life-threatening condition. Symptoms include agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle twitching, tremor, sweating, diarrhoea, and high fever. Seek immediate medical attention if you develop these symptoms.
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram) | Antidepressant | Combined serotonergic activity increases risk of serotonin syndrome | Use with caution; monitor closely for serotonin syndrome symptoms |
| SNRIs (venlafaxine, duloxetine, desvenlafaxine) | Antidepressant | Combined serotonergic activity increases risk of serotonin syndrome | Use with caution; monitor closely for serotonin syndrome symptoms |
| Lithium | Mood stabiliser | Additive serotonergic effect; increased risk of serotonin syndrome | Monitor carefully if concurrent use is necessary |
| St. John's Wort (Hypericum perforatum) | Herbal supplement | Serotonergic activity; may increase risk of serotonin syndrome | Avoid concurrent use |
| Nadolol / Metoprolol / Timolol | Beta-blockers | Unlike propranolol, these beta-blockers do not significantly alter rizatriptan levels | No dose adjustment needed; these are preferred alternatives to propranolol |
Note that other beta-blockers such as nadolol, metoprolol, and timolol do not significantly affect rizatriptan metabolism and do not require a dose reduction. The interaction is specific to propranolol.
What Is the Correct Dosage of Rizatriptan?
The recommended dose for adults is 10 mg taken at the onset of migraine headache. A second dose may be taken after at least 2 hours if the migraine returns. The maximum dose is 30 mg in 24 hours. If you take propranolol, use 5 mg per dose (max 15 mg/24 hours).
Rizatriptan should be taken as early as possible after the onset of the migraine headache phase. It should not be taken during the aura phase before the headache begins, as this may reduce its effectiveness. If you are unsure whether your headache is a migraine, consult your doctor before taking rizatriptan.
Adults (18 years and over)
Standard Dose
Recommended dose: 10 mg as a single dose at the onset of migraine headache
Second dose: If the migraine returns or does not fully resolve, a second 10 mg dose may be taken after a minimum interval of 2 hours
Maximum dose: 30 mg (three 10 mg doses) in any 24-hour period
Patients Taking Propranolol
Reduced dose: 5 mg per dose
Maximum dose: 15 mg (three 5 mg doses) in any 24-hour period
This dose reduction is necessary because propranolol increases rizatriptan blood levels by approximately 70%.
Orodispersible (Wafer/Melt) Tablets
Administration: Place the orodispersible tablet on the tongue and allow it to dissolve with saliva. It can be taken without water. Do not push the tablet through the blister foil – peel back the foil to remove the tablet.
The orodispersible formulation has a slightly slower absorption rate compared to conventional tablets but provides the same overall efficacy. It is particularly useful for patients with migraine-related nausea.
Patients with Liver Impairment
No dose adjustment is required for patients with mild to moderate hepatic impairment. Rizatriptan is contraindicated in patients with severe hepatic impairment.
Patients with Kidney Impairment
No dose adjustment is necessary for patients with renal impairment, as only a small proportion of rizatriptan is excreted unchanged by the kidneys.
Children and Adolescents
The safety and efficacy of rizatriptan in children under 18 years of age have not been established. Rizatriptan is not recommended for use in the paediatric population.
If Rizatriptan Does Not Work
If the first dose of rizatriptan does not provide any relief, do not take a second dose for the same attack. A second dose has not been shown to be effective for a migraine that did not respond to the first dose. You may use a different type of pain reliever (such as paracetamol or an NSAID) instead. Consult your doctor if rizatriptan repeatedly fails to relieve your migraines.
Overdose
Taking too much rizatriptan can cause elevated blood pressure, cardiovascular symptoms, dizziness, fainting, and other serious effects. In case of overdose, seek immediate medical attention by contacting your local emergency services or poison control centre. There is no specific antidote for rizatriptan. Standard supportive care should be provided, including monitoring of cardiovascular status for at least 12 hours.
What Are the Side Effects of Rizatriptan?
The most common side effects of rizatriptan include dizziness, drowsiness, fatigue, and a sensation of chest tightness or pressure. Serious but rare side effects include cardiac events and serotonin syndrome. Most side effects are transient and resolve within a few hours.
Like all medicines, rizatriptan can cause side effects, although not everybody gets them. Most side effects are mild and short-lived, typically resolving within 1–2 hours. If any side effects become severe or persistent, consult your doctor.
- Chest pain, tightness, pressure, or heaviness that is severe or does not resolve quickly (possible cardiac event)
- Sudden severe headache unlike any previous headache (possible cerebrovascular event)
- Signs of allergic reaction: swelling of face, lips, tongue, or throat; difficulty breathing; hives
- Signs of serotonin syndrome: agitation, confusion, rapid heartbeat, high fever, muscle rigidity, twitching
- Sudden weakness or numbness on one side of the body, difficulty speaking (signs of stroke)
- Severe stomach pain with or without bloody diarrhoea (possible ischaemic colitis)
Common
May affect up to 1 in 10 people
- Dizziness
- Drowsiness and fatigue
- Weakness (asthenia)
- Nausea
- Dry mouth
- Headache (non-migraine)
- Sensation of tingling or numbness (paraesthesia)
- Throat, neck, jaw, or chest tightness, pressure, or heaviness (triptan sensations)
- Flushing (hot flushes)
- Abdominal discomfort
Uncommon
May affect up to 1 in 100 people
- Palpitations (awareness of heartbeat)
- Tachycardia (increased heart rate)
- Diarrhoea or vomiting
- Muscle pain
- Tremor
- Vertigo
- Blurred vision
- Insomnia
- Decreased mental acuity
- Neck stiffness or pain
- Thirst
Rare and Very Rare
May affect up to 1 in 1,000 people or fewer
- Angioedema (swelling of face, lips, tongue) – allergic reaction
- Anaphylaxis – severe, life-threatening allergic reaction
- Serotonin syndrome (with concurrent serotonergic drugs)
- Myocardial ischaemia or infarction (heart attack) – in patients with cardiovascular risk factors
- Stroke or transient ischaemic attack
- Peripheral vascular ischaemia
- Ischaemic colitis (reduced blood flow to the bowel)
- Seizures
- Toxic epidermal necrolysis and Stevens-Johnson syndrome
- Wheezing and dyspnoea (shortness of breath)
The chest tightness, pressure, and heaviness that some patients experience with rizatriptan (known as "triptan sensations") are generally benign and not related to the heart. However, since these symptoms can occasionally indicate cardiac ischaemia, patients who experience significant or persistent chest symptoms should be evaluated by a doctor, particularly if they have cardiovascular risk factors.
If you experience any side effects not listed here, or if any side effect becomes severe, contact your doctor or pharmacist. Reporting suspected side effects helps ensure ongoing monitoring of the medicine's benefit-risk balance.
How Should You Store Rizatriptan?
Store rizatriptan at room temperature (below 25°C / 77°F), away from moisture and direct light. Keep out of the reach and sight of children. Do not use after the expiry date printed on the packaging.
Store rizatriptan tablets in their original packaging to protect from moisture and light. The orodispersible tablets are individually sealed in blister packs and must remain in their sealed packaging until immediately before use, as they are sensitive to moisture. When removing an orodispersible tablet, peel back the foil carefully – do not push the tablet through the blister, as this may damage it.
Check the expiry date (marked "EXP" on the carton and blister) before taking any tablets. The expiry date refers to the last day of the stated month. Do not flush unused tablets down the toilet or throw them in household waste. Return any unused or expired medication to your pharmacy for safe disposal.
What Does Rizatriptan Contain?
Each rizatriptan tablet contains the active ingredient rizatriptan (as benzoate salt) and several inactive ingredients. Conventional tablets are available as 5 mg and 10 mg strengths. Orodispersible tablets are lyophilised wafers that dissolve on the tongue.
Active Ingredient
The active substance is rizatriptan. Each 5 mg tablet contains rizatriptan benzoate equivalent to 5 mg rizatriptan. Each 10 mg tablet contains rizatriptan benzoate equivalent to 10 mg rizatriptan.
Inactive Ingredients (Excipients) – Conventional Tablets
The other ingredients typically include: lactose monohydrate, microcrystalline cellulose, pregelatinised starch, iron oxide red (5 mg), magnesium stearate, and hypromellose. Exact excipients may vary between manufacturers.
Inactive Ingredients (Excipients) – Orodispersible Tablets
The orodispersible tablets typically contain: gelatin, mannitol, glycine, aspartame (E951), and peppermint flavour. Note: The orodispersible tablets contain aspartame, a source of phenylalanine, which may be harmful to patients with phenylketonuria (PKU). Each 10 mg orodispersible tablet contains approximately 2.1 mg phenylalanine.
Tablet Appearance and Packaging
5 mg conventional tablets: Light pink, capsule-shaped, film-coated tablets engraved with identification markings.
10 mg conventional tablets: Pink, capsule-shaped, film-coated tablets engraved with identification markings.
Orodispersible tablets: White to off-white, round, freeze-dried wafers supplied in individual blister packs.
Available in blister packs of 3, 6, 12, and 18 tablets. Not all pack sizes may be marketed in your country.
How Does Rizatriptan Work in the Body?
Rizatriptan works by selectively activating serotonin 5-HT1B and 5-HT1D receptors. This causes constriction of dilated intracranial blood vessels, inhibits the release of pro-inflammatory neuropeptides from trigeminal nerve endings, and blocks pain signal transmission in the brainstem, providing rapid relief from migraine headache and associated symptoms.
During a migraine attack, several pathological processes occur in the brain: intracranial blood vessels dilate, the trigeminal nerve system becomes activated, and pro-inflammatory neuropeptides (including calcitonin gene-related peptide, or CGRP, substance P, and neurokinin A) are released around the blood vessels. This triggers neurogenic inflammation and sensitises pain receptors, resulting in the characteristic throbbing headache.
Rizatriptan targets three key mechanisms in migraine pathophysiology:
- Cranial vasoconstriction (5-HT1B receptors): Rizatriptan activates 5-HT1B receptors on intracranial blood vessels, causing selective constriction of the dilated meningeal and cerebral arteries. This vasoconstriction is highly selective for cranial vasculature and does not significantly affect peripheral blood vessels or blood pressure at therapeutic doses
- Trigeminal nerve inhibition (5-HT1D receptors): Rizatriptan activates 5-HT1D receptors on trigeminal nerve endings, inhibiting the release of pro-inflammatory neuropeptides (CGRP, substance P) that drive neurogenic inflammation and pain sensitisation around the cranial blood vessels
- Central pain modulation (5-HT1B/1D receptors): Rizatriptan acts on 5-HT1B and 5-HT1D receptors in the trigeminal nucleus caudalis in the brainstem, blocking the transmission of pain signals from the trigeminal system to higher brain centres, thereby reducing the perception of migraine pain
Pharmacokinetic Profile
After oral administration of a conventional tablet, rizatriptan is rapidly absorbed from the gastrointestinal tract. Peak plasma concentrations are reached within approximately 1–1.5 hours. For orodispersible tablets, peak concentrations occur at approximately 1.6–2.5 hours. The oral bioavailability is approximately 45%, reflecting moderate first-pass metabolism.
Rizatriptan is primarily metabolised by monoamine oxidase type A (MAO-A) to the pharmacologically inactive indole acetic acid metabolite. A minor metabolic pathway produces an active N-monodesmethyl metabolite with similar 5-HT1B/1D activity, but its plasma concentrations are too low to contribute significantly to the therapeutic effect.
The elimination half-life is approximately 2–3 hours. Approximately 82% of the dose is excreted in urine (14% as unchanged drug) and 12% in faeces. Plasma protein binding is low (14%), which contributes to the drug's rapid onset of action and ability to cross the blood-brain barrier effectively.
Frequently Asked Questions About Rizatriptan
Rizatriptan is one of the fastest-acting triptans available. Most patients begin to experience pain relief within 30 minutes of taking a 10 mg dose, and the majority achieve significant relief within 2 hours. The orodispersible (wafer) form is absorbed at a similar rate but is more convenient for patients experiencing nausea during a migraine attack, as it dissolves on the tongue without water. For best results, take rizatriptan as early as possible after the headache phase begins.
Clinical trials and meta-analyses suggest that rizatriptan 10 mg provides faster onset of pain relief compared to sumatriptan 100 mg, with higher rates of pain-free response at 2 hours (approximately 40% vs 30%). However, both are effective first-line triptans for acute migraine. Rizatriptan is also available as an orodispersible tablet, which is convenient for patients with nausea. Sumatriptan has more formulation options, including nasal spray and subcutaneous injection for patients who cannot take oral medication. The choice between them depends on individual response, tolerability, and clinical factors. Some patients respond better to one triptan than another.
You may take a second dose of rizatriptan if your migraine returns or does not fully resolve, but you must wait at least 2 hours between doses. The maximum dose is 30 mg (three 10 mg tablets) within any 24-hour period, or 15 mg (three 5 mg tablets) if you are taking propranolol. If the first dose does not provide any relief at all, do not take a second dose for the same attack. To reduce the risk of medication-overuse headache, rizatriptan should not be used on more than 10 days per month on a regular basis.
Triptans including rizatriptan are generally most effective when taken at the onset of the headache phase, rather than during the aura. Clinical studies suggest that taking triptans during the aura, before the headache begins, may be less effective and can sometimes delay rather than prevent the headache. The current recommendation from the International Headache Society (IHS) is to wait until the headache phase starts and then take rizatriptan as early as possible for optimal efficacy.
The safety of rizatriptan during pregnancy has not been fully established. Limited human data from pregnancy registries have not shown a clear pattern of birth defects, but the evidence is insufficient to confirm safety. Rizatriptan should only be used during pregnancy if the potential benefit justifies the potential risk. If you are pregnant or planning to become pregnant, consult your doctor before taking rizatriptan. Your doctor may recommend paracetamol (acetaminophen), which has a more established safety profile during pregnancy, or other non-triptan alternatives for migraine relief.
Yes, using rizatriptan or any acute migraine medication too frequently can lead to medication-overuse headache (MOH), also called rebound headache. This occurs when triptans are used on 10 or more days per month for 3 consecutive months or longer. MOH results in more frequent, persistent, and harder-to-treat headaches, creating a vicious cycle of increasing medication use. If you find yourself needing rizatriptan more than 2–3 times per week, speak with your doctor about starting a preventive migraine treatment such as propranolol, topiramate, amitriptyline, or a CGRP monoclonal antibody to reduce your attack frequency.
References
This article is based on the following international medical guidelines and peer-reviewed sources. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews of randomised controlled trials.
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (ICHD-3). Cephalalgia. 2018;38(1):1–211. doi:10.1177/0333102417738202
- Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60(6):1259–1287. doi:10.2165/00003495-200060060-00003
- Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. The Lancet. 2001;358(9294):1668–1675. doi:10.1016/S0140-6736(01)06711-3
- National Institute for Health and Care Excellence (NICE). Headaches in over 12s: diagnosis and management. NICE guideline [CG150]. Updated 2021.
- European Headache Federation (EHF). Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition). The Journal of Headache and Pain. 2019;20:57. doi:10.1186/s10194-019-1007-2
- Oldman AD, Smith LA, McQuay HJ, Moore RA. Rizatriptan for acute migraine. Cochrane Database of Systematic Reviews. 2007;(1):CD003221. doi:10.1002/14651858.CD003221.pub2
- Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. New England Journal of Medicine. 2002;346(4):257–270. doi:10.1056/NEJMra010917
- European Medicines Agency (EMA). Rizatriptan – Summary of Product Characteristics. EMA product information database. Accessed February 2026.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in neurology, clinical pharmacology, and headache medicine.
Medical Writers
Board-certified physicians specialising in neurology, headache medicine, and clinical pharmacology with documented academic and clinical experience.
Medical Reviewers
Independent review board ensuring clinical accuracy, adherence to international guidelines (IHS, EHF, NICE, WHO), and evidence level 1A standards.
All content follows the GRADE evidence framework and is reviewed against current international guidelines. We have no commercial funding or pharmaceutical sponsorship. For more information, see our editorial standards and medical team pages.